Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Ambit Biosciences Corporation
ClinicalTrials.gov Identifier:
NCT01565668
First received: March 27, 2012
Last updated: September 19, 2013
Last verified: September 2013
  Purpose

This study will evaluate two doses of Quizartinib in patients with relapsed or refractory acute myeloid leukemia who are also FMS-like tyrosine kinase - internal tandem duplication ( FLT3-ITD) positive. Patient will be randomly assigned in a 1:1 ratio to one of two treatment arms. Both treatment arms will receive Quizartinib but at different doses. The study treatment is taken orally in 28 day cycles until either disease progression occurs or an unacceptable toxicity occurs. In addition to the study assessments to evaluate the disease, blood will be drawn to measure drug levels and biomarkers. Patients will be followed for survival at three month intervals after the end of treatment.


Condition Intervention Phase
Leukemia, Myeloid, Acute
Drug: AC220
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Open-Label Study of the Safety and Efficacy of Two Doses of Quizartinib (AC220; ASP2689) in Subjects With FLT3-ITD Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Resource links provided by NLM:


Further study details as provided by Ambit Biosciences Corporation:

Primary Outcome Measures:
  • Composite Complete Response (CRc) [ Time Frame: Evaluated after two complete 28 day cycles ] [ Designated as safety issue: No ]
    CRc is defined as Complete remission (CR) + Complete remission with incomplete platelet recovery (CRp) + Complete remission with incomplete hematological recovery (CRi)

  • Grade 2 or higher QT interval corrected for heart rate using Fridericia's factor (QTcF) prolongation at each dose level AC220 [ Time Frame: Evaluated after two complete 28 day cycles ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Complete Remission (CR) [ Time Frame: Evaluated after two complete 28 day cycles ] [ Designated as safety issue: No ]
    Subject must have bone marrow regenerating normal hematopoietic cells and achieve a morphologic leukemia-free state (< 5% bone marrow blasts in bone marrow, no blasts with Auer rods and no persistence of extramedullary disease) and must have an absolute neutrophil count (ANC) ≥ 1x109/L and platelet count ≥ 100 x 109/L and they will be red blood cell (RBC) and platelet transfusion independent (defined as 4 weeks without RBC transfusions and 1 week without platelet transfusion).

  • Overall Survival (OS) [ Time Frame: Evaluated at end of study, up to 6 months ] [ Designated as safety issue: No ]
    Time from randomization until death

  • Event free survival (EFS) [ Time Frame: Evaluated at end of study, up to 6 months ] [ Designated as safety issue: No ]
    Time from randomization until documented relapse or death

  • Leukemia free survival (LFS) [ Time Frame: Evaluated at end of study, up to 6 months ] [ Designated as safety issue: No ]
    Time from first CRc until documented relapse or death

  • Duration of remission [ Time Frame: Evaluated at end of study, up to 6 months ] [ Designated as safety issue: No ]
    Time from first documented remission until documented relapse

  • Safety assessed by recording adverse events, laboratory assessments, vital signs, electrocardiograms (ECGs), and Eastern Cooperative Oncology Group (ECOG) performance scores [ Time Frame: Continuous, up to 6 months from study end ] [ Designated as safety issue: No ]
  • Time to treatment response (TTR) [ Time Frame: Evaluated at end of study, up to 6 months ] [ Designated as safety issue: No ]
    Time from randomization until the first measured response

  • Percentage of subjects undergoing hematopoietic stem cell transplantation (HSCT) [ Time Frame: Evaluated at end of study, up to 6 months ] [ Designated as safety issue: No ]

Enrollment: 76
Study Start Date: April 2012
Estimated Study Completion Date: November 2013
Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AC220 Dose Level 1 Drug: AC220
oral
Other Names:
  • Quizartinib
  • ASP2689
Experimental: AC220 Dose Level 2 Drug: AC220
oral
Other Names:
  • Quizartinib
  • ASP2689

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject has morphologically documented primary AML or AML secondary to myelodysplastic syndrome (MDS) as defined by the World Health Organization (WHO) criteria, as determined by pathology review at the treating institution and has relapsed or is refractory after 1 second line (salvage) regimen or after HSCT
  • Subject is positive for FLT3-ITD activating mutation in bone marrow or peripheral blood (>10% allelic ratio)
  • ECOG performance status of 0 to 2
  • In the absence of rapidly progressing disease clearly documented by the investigator, the interval from prior treatment to time of AC220 administration will be at least 2 weeks (14 days) for prior cytotoxic agents or at least 5 half-lives for prior noncytotoxic agents, including immunosuppressive therapy post HSCT
  • Persistent chronic clinically significant nonhematological toxicities from prior treatment (including chemotherapy, kinase inhibitors, immunotherapy, experimental agents, radiation, HSCT, or surgery) must be Grade ≤ 1
  • Patients - both males and females - with reproductive potential are eligible

Exclusion Criteria:

  • Subject received previous treatment with AC220
  • Subject has a diagnosis of acute promyelocytic leukemia
  • Subject has a diagnosis of chronic myelogenous leukemia (CML) in blast crisis
  • Subject has AML or antecedent MDS secondary to prior chemotherapy
  • Subject has had HSCT and has either of the following:
  • Donor lymphocyte infusion (DLI) is not permitted during the study or < 30 days prior to study entry
  • Subject has clinically active CNS leukemia. A subject is considered eligible if CNS leukemia is controlled and subject is receiving intrathecal (IT) therapy at study entry. Subjects should continue to receive IT therapy (or cranial radiation) as clinically indicated
  • Subject has received concurrent chemotherapy, immunotherapy, or radiotherapy within 14 days prior to the first dose of AC220, or any ancillary therapy that is considered to be investigational (i.e., used for non-approved indications(s) and in the context of a research investigation) within 30 days or 5 half-lives (whichever is longer) prior to the first dose of study drug
  • Subject requires treatment with concomitant drugs that prolong QT/QTc interval or with strong inhibitors or inducers of cytochrome P450- isozyme3A4 (CYP3A4) with the exception of antibiotics, antifungals, and antivirals that are used as standard of care post-transplant or to prevent or treat infections and other such drugs that are considered absolutely essential for the care of the subject
  • Subject requires treatment with anticoagulant therapy
  • Subject has a known positive test for human immunodeficiency virus, hepatitis C, or hepatitis B surface antigen
  • Subject had major surgery within 4 weeks prior to first dose of AC220
  • Subject has uncontrolled or significant cardiovascular disease, including
  • Subject has a pre-existing disorder predisposing the subject to a serious or life-threatening infection (e.g. cystic fibrosis, congenital or acquired immunodeficiency, bleeding disorder, or cytopenias not related to AML)
  • Subject has an active uncontrolled acute or chronic systemic fungal, bacterial, viral, or other infection
  • Subject has any of the following laboratory values:
  • Subject is a female with a positive pregnancy test, pregnant, or breastfeeding
  • Subject has any medical, psychiatric, addictive or other kind of disorder which compromises the ability of the subject to give written informed consent and/or to comply with procedures
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01565668

  Hide Study Locations
Locations
United States, California
UCLA School of Medicine
Los Angeles, California, United States, 90095
United States, Illinois
University of Chicago
Chicago, Illinois, United States, 60637
Northwestern University
Chicago, Illinois, United States, 60611
United States, Maryland
University of Maryland Greenebaum Cancer Center
Baltimore, Maryland, United States, 21201
John Hopkins University
Baltimore, Maryland, United States, 21231
United States, Massachusetts
Tufts University School of Medicine-Tufts Medical Center
Boston, Massachusetts, United States, 02111
United States, Minnesota
University of Minnesota
Minneapolis, Minnesota, United States, 55455
Mayo Clinic
Rochester, Minnesota, United States, 55905
United States, New Jersey
Hackensack University Medical Center
Hackensack, New Jersey, United States, 07601
United States, New York
Weill Cornell Medical College
New York, New York, United States, 10065
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10021
United States, Pennsylvania
Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania, United States, 17033
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
United States, South Carolina
Medical University of South Carolina, Hollings Cancer Center
Charleston, South Carolina, United States, 29403
United States, Tennessee
Vanderbilt University, Vanderbilt Ingram Cancer Center
Nashville, Tennessee, United States, 37232
United States, Texas
UT Southwestern Medical Center, Simmons Cancer Center
Dallas, Texas, United States, 75390
MD Anderson
Houston, Texas, United States, 77030
United States, Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States, 98109
France
CHU d'Angers
Angers, France, 49033
CHU de Grenoble
Grenoble, France, 38043
Hôpital Saint Antoine
Paris, France, 75571
Hôpital Haut Lévêque
Pessac, France, 33600
Italy
Universitaria Policlinico S. Orsola Malpighi, Institute of Hemtology "L. & A. Seragnoli"
Bologna, Italy, 40138
United Kingdom
Nottingham University Hospitals
Nottingham, England, United Kingdom
Sponsors and Collaborators
Ambit Biosciences Corporation
Investigators
Study Director: Guy Gammon, MB, BS, MRCP Medical Monitor, Ambit Biosciences Corporation
  More Information

No publications provided

Responsible Party: Ambit Biosciences Corporation
ClinicalTrials.gov Identifier: NCT01565668     History of Changes
Other Study ID Numbers: 2689-CL-2004, 2011-005408-13
Study First Received: March 27, 2012
Last Updated: September 19, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Ambit Biosciences Corporation:
FLT3-ITD positive Acute Myeloid Leukemia (AML)
AC220
Relapse
Refractory

Additional relevant MeSH terms:
Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms
Neoplasms by Histologic Type

ClinicalTrials.gov processed this record on October 29, 2014